Biopeak Raises USD 3.5 Million to Expand AI-Driven Health Clinics
"We're at a unique point where developments in molecular diagnostics, AI, and imaging allow us to understand the human body in unprecedented ways," says Rishi Pardal, Co-founder and CEO of Biopeak
Opinions expressed by Entrepreneur contributors are their own.
You're reading Entrepreneur India, an international franchise of Entrepreneur Media.
Biopeak, a wellness and longevity-focused startup headquartered in Bengaluru, has raised USD 3.5 million (approximately INR 29 crore) in seed funding from a group of notable investors. The round saw participation from Accel founding partner Prashanth Prakash, Claypond Capital--the family office of Manipal Group chairman Ranjan Pai and NKSquared, the investment arm of Zerodha co-founder Nikhil Kamath.
Founded in 2024 by Rishi Pardal and Shiva Subramanian, Biopeak delivers personalised health services through its own clinics, combining advanced diagnostics, molecular science, and artificial intelligence (AI) to monitor early signs of physiological change. The company launched its first clinic in Bengaluru in March 2025.
The funding will be used to expand Biopeak's clinic footprint across key Indian cities and strengthen its AI-based diagnostic and care delivery platform.
"We're at a unique point where developments in molecular diagnostics, AI, and imaging allow us to understand the human body in unprecedented ways," said Rishi Pardal, Co-founder and CEO of Biopeak. "Our platform translates these insights into actionable, individualised health plans aimed at extending one's healthspan, not just lifespan."
Biopeak's approach includes a suite of diagnostic tools such as microbiome mapping, organic acid profiling, salivary cortisol rhythm analysis, and whole-exome functional genomics. These are integrated with non-invasive imaging technologies including MRI, CT, DXA, and ECHO, along with tissue-level screenings to assess toxin levels, mineral balance, and oxidative stress.
Clients typically undergo more than six hours of detailed consultations guided by a dedicated health manager and a multidisciplinary team of specialists. Health plans are updated regularly based on follow-up tests and consultations.
Commenting on the investment, Prashanth Prakash said, "As India's population ages, our challenge is to build systems that not only extend life but also improve the quality of those extended years. Geroscience, early interventions, and scalable healthcare models will be central to this shift."
Prakash, who also mentors Biopeak, is the Founding Patron of Longevity India, a platform focused on ageing research and interventions tailored for India's demographic needs.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
39 minutes ago
- Yahoo
Prediction: This Hot Artificial Intelligence (AI) Semiconductor Stock Will Skyrocket After June 25
Micron Technology stock has been in red-hot form on the stock market over the past couple of months, and its upcoming quarterly report on June 25 could give it another boost. Micron is on track to deliver outstanding growth in its revenue and earnings, driven by the terrific demand for the company's high-bandwidth memory chips. The stock's attractive valuation makes it a no-brainer buy going into its earnings report. 10 stocks we like better than Micron Technology › Micron Technology (NASDAQ: MU) stock has made a sharp move higher over the past couple of months -- gaining an impressive 37% as of this writing -- driven by the broader recovery in technology stocks. And it won't be surprising to see this semiconductor stock getting a big shot in the arm when it releases its fiscal 2025 third-quarter results after the market closes on June 25. Micron is heading into its quarterly report with a major catalyst in the form of artificial intelligence (AI) on its side, which could allow the company to deliver better-than-expected numbers and guidance and send its stock even higher. Let's look at the reasons why that may be the case. Micron's fiscal Q3 guidance calls for $8.8 billion in revenue at the midpoint of its guidance range. That would be a massive increase over the year-ago period's revenue of $6.8 billion. Meanwhile, the company's adjusted earnings are forecast to jump by just over 2.5 times on a year-over-year basis. Investors, however, shouldn't forget that the booming demand for high-bandwidth memory (HBM) that goes into AI graphics processing units (GPUs) manufactured by the likes of Nvidia and AMD could allow Micron to exceed its guidance. Micron's HBM has been selected for powering Nvidia's GB200 and GB300 Blackwell systems, and the good news is that the latter reported solid numbers recently. Nvidia's data center revenue shot up 73% year over year to $39 billion in the first quarter of fiscal 2026, with the Blackwell AI GPUs accounting for 70% of the segment's revenue. Nvidia pointed out that it has almost completed its transition from the previous-generation Hopper platform to GPUs based on the latest Blackwell architecture. What's worth noting here is that the company's Blackwell GPUs are equipped with larger HBM chips to enable higher bandwidth and data transmission. Specifically, Nvidia's Hopper H200 GPU was equipped with 141 gigabytes (GB) of HBM. That has been upgraded to 192 GB on Nvidia's B200 Blackwell processor, while the more powerful B300 packs a whopping 288 GB of HBM3e memory. Micron management remarked on the company's March earnings conference call that it started volume shipments of HBM3e memory to its third large customer, suggesting that it could indeed be supplying memory chips for Nvidia's latest generation processors. Importantly, the terrific demand for HBM has created a favorable pricing scenario for the likes of Micron. The company is reportedly looking to hike the price of its HBM chips by 11% this year. It has sold out its entire HBM capacity for 2025 and is negotiating contracts for next year, and it won't be surprising to see customers paying more for HBM considering its scarcity. This combination of higher HBM volumes and the potential increase in price explains why Micron's top and bottom lines are set to witness remarkable growth when it releases its earnings later this month. Additionally, even more chipmakers are set to integrate HBM into their AI accelerators. Broadcom and Marvell Technology, which are known for designing custom AI processors for major cloud computing companies, have recently developed architectures supporting the integration of HBM into their platforms. So, Marvell's addressable market is likely to get bigger thanks to AI, setting the stage for a potential acceleration in the company's growth. Micron stock has rallied impressively in the past couple of months. The good part is that the company is still trading at just 23 times earnings despite this surge. The forward earnings multiple of 9 is even more attractive, indicating that Micron's earnings growth is set to take off. Consensus estimates are projecting a whopping 437% increase in Micron's earnings this year, followed by another solid jump of 57% in the next fiscal year. All this indicates why the stock's median 12-month price target of $130 points toward a 27% jump from current levels. However, this AI stock could do much better than that on account of the phenomenal earnings growth that it is projected to clock, which is why investors can consider buying it hand over fist before its June 25 report that could supercharge its recent rally. Before you buy stock in Micron Technology, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Micron Technology wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $669,517!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $868,615!* Now, it's worth noting Stock Advisor's total average return is 792% — a market-crushing outperformance compared to 171% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Harsh Chauhan has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Advanced Micro Devices and Nvidia. The Motley Fool recommends Broadcom and Marvell Technology. The Motley Fool has a disclosure policy. Prediction: This Hot Artificial Intelligence (AI) Semiconductor Stock Will Skyrocket After June 25 was originally published by The Motley Fool
Yahoo
an hour ago
- Yahoo
Trillium Health to celebrate annual White Party fundraiser
ROCHESTER, N.Y. (WROC) — Trillium Health will host an evening of entertainment and advocacy for its largest annual fundraising event on Saturday. The White Party is held to advance Trillium Health's effort to end the HIV epidemic and provide individuals with accessible healthcare and resources. Trillium Health is a Federally Qualified Health Center that takes a holistic approach to providing comprehensive care to over 20,000 patients throughout the Greater Rochester area. Formerly known as the Community Health Network before expanding to Trillium Health in 2016, the organization was founded by Dr. William Valenti and Dr. Steven Scheibel as an HIV and AIDS clinic in 1989. They also serve the community with primary care and additional health services. Pittsford CommUNITY to host pride walk, celebration 'We are beyond excited to host The White Party once again and bring our community together for an unforgettable night. This event plays a critical role in supporting our work, ensuring we can continue providing accessible care to all, no matter their financial situation,' President and CEO of Trillium Health, Jason Barnecut-Kearns, said. The ticketed event will include an open bar, gourmet tasting stations, and dancing for attendees from 7 p.m. until 11 p.m. at the Mercantile on Main. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
an hour ago
- Yahoo
Billionaire Stanley Druckenmiller Has Unloaded Shares of Last Year's 2 Top Performing AI Stocks and Is Piling Into a Growth Stock That Has Climbed 150% in 3 Years
Druckenmiller has a stunning investment track record, regularly delivering double-digit percentage annual returns with no money-losing years. In recent times, the billionaire has benefited from investments in some of today's top growth stocks. 10 stocks we like better than Eli Lilly › You don't have to be a billionaire to invest like one -- and reap the rewards. Any of us can look at the moves made by the world's most successful investors and follow those that also fit into our investment strategy. Billionaire fund managers have proven their strengths as investors over time, making them excellent guides for novices on the wealth-building path. With that in mind, let's consider the recent moves made by Stanley Druckenmiller, founder of the Duquesne Family Office. Over the past few quarters, he closed his position in last year's two top-performing S&P 500 and Dow Jones Industrial Average artificial intelligence (AI) stocks, and just recently, he increased his position in a growth stock that has soared by 150% over the past three years. Could taking those cues be a smart move for you? So, first, a bit about why Druckenmiller is a billionaire worth watching and potentially following. He founded Duquesne Capital Management in the early 1980s and ran the fund for 30 years. Over that time period, he delivered a truly remarkable annualized average return of 30% -- and importantly, never had a money-losing year. Since then, he has shifted his focus to his family office, where he invests in stocks across industries and oversees $3 billion in securities. Now, let's consider his recent moves, starting with a major one. In the third quarter, Druckenmiller closed out his position in AI chip market leader Nvidia (NASDAQ: NVDA), a company that climbed a bit further from there, becoming the Dow Jones Industrial Average component that delivered the biggest annual gain of 2024. The investor originally bought Nvidia shares in the fourth quarter of 2022, and from the end of that quarter through the end of last year's third quarter, they climbed by more than 700%. So this clearly was a winning investment for Druckenmiller, though in a Bloomberg interview, he expressed regret about the timing of the sale, and said he would consider buying Nvidia stock again at the right price. Druckenmiller's second big sale came in the first quarter of this year: He closed out his position in Palantir Technologies (NASDAQ: PLTR), a stock he bought a year earlier. Last year, the AI software company generated the biggest gain in the S&P 500, climbing by 340%. Meanwhile, Druckenmiller increased his position in another growth stock: pharma giant Eli Lilly (NYSE: LLY), which in recent quarters has delivered double-digit percentage revenue gains. That growth came largely thanks to its position in a high-growth market with solid long-term potential: weight loss drugs. Druckenmiller increased his Lilly holding by 52% in the first quarter and now owns 94,830 shares worth about $73 million as of the close of trading Friday. Lilly represents nearly 2.6% of the billionaire's portfolio, up from about 1.3% in the previous quarter. He initially bought the stock in 2024's fourth quarter, so he clearly is building a position in it, and sees opportunity for growth ahead. Lilly sells a wide variety of medicines, but investors have focused on its GLP-1 agonist tirzepatide in recent quarters -- and for good reason. Tirzepatide is sold under the name Mounjaro for type 2 diabetes and Zepbound for weight loss, and both drugs are generating blockbuster revenues. Doctors have prescribed either one for weight loss, and demand has been so high that last year, both were on the Food and Drug Administration's shortage list. These drugs should continue to generate sales growth due to ongoing high demand; analysts at Goldman Sachs forecast that the weight loss drug market will be about $95 billion annually by 2030. One more element may supercharge Lilly's growth in this market. Mounjaro, Zepbound, and the competing GLP-1 drugs on the market today all must be administered via injection, but Lilly has been developing a new weight loss candidate in pill form. Phase 3 trials have produced strong data for the pill, dubbed orforglipron, and Lilly says it will apply for regulatory review in the weight loss indication by the end of this year. The convenience of a weight loss pill that is as effective as the injectables could help orforglipron (and Lilly) take a leading share of the market in the years to come. So the drugmaker's growth may be far from over. Should you follow Druckenmiller's lead, exit Nvidia and Palantir (if you own them), and get in on Lilly shares? All three of these companies are leaders in exciting growth markets and could gain over the long term, so your decisions should depend on your investment strategy. If you're a cautious investor and like passive income, Eli Lilly is a great choice to own because, while it does offer share price growth potential, it also offers the safety and steady dividends of an established pharma player. If you're an aggressive investor, though, you may want to favor the AI story and continue along with Nvidia and/or Palantir over the long term. Before you buy stock in Eli Lilly, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Eli Lilly wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $669,517!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $868,615!* Now, it's worth noting Stock Advisor's total average return is 792% — a market-crushing outperformance compared to 171% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Adria Cimino has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Nvidia and Palantir Technologies. The Motley Fool has a disclosure policy. Billionaire Stanley Druckenmiller Has Unloaded Shares of Last Year's 2 Top Performing AI Stocks and Is Piling Into a Growth Stock That Has Climbed 150% in 3 Years was originally published by The Motley Fool
